Datar Cancer Genetics announced that it received FDA breakthrough device designation for its TriNetra-Glio blood test. TriNetra-Glio aids in the diagnosis of brain tumors. It represents the third test from Datar to receive the FDA’s breakthrough device designation. The test joins Datar’s early-stage breast and prostate cancer detection tests. According to a news release, the […]
Datar Cancer Genetics
FDA grants breakthrough nod for Datar’s early-stage prostate cancer detection blood test
Datar Cancer Genetics announced today that it received FDA breakthrough device designation for its cancer-detecting blood test. Boston-based Datar designed its TriNetra-Prostate blood test to detect early-stage prostate cancer. It follows the company’s early-stage breast cancer detection test, which garnered a breakthrough nod in November 2021. The company said in a news release that studies […]
Datar Cancer Genetics wins FDA breakthrough nod for breast cancer detection blood test
Datar Cancer Genetics announced today that it received FDA breakthrough device designation for its TriNetra blood test. The company designed its TriNetra blood test to detect early-stage breast cancer using proprietary technology that detects circulating tumor cells (CTCs) specific to breast cancer. According to a news release, TriNetra can detect even Stage 0 (DCIS) and […]